were among the best-performing health-related stocks Friday, jumping 18% after the genetics diagnostics company said its first-quarter results will top its previous guidance.
In February, the company projected earnings ranging from break-even to 2 cents a share and revenue of $22 million to $24 million. Analysts polled by Thomson First Call project earnings of 1 cent a share on revenue of $23.6 million. Last year, the company recorded a first-quarter loss of $1.2 million, or 3 cents a share, on revenue of $15.1 million. The company plans to issue its first-quarter results on April 18. Shares were trading up $4.05 to $26.13.
fell 4% after the biopharmaceutical company priced 10 million shares of stock at $11.75 apiece, resulting in net proceeds of about $111.6 million. The price represents a 4% discount to Thursday's closing price of $12.28. In addition to funding general needs, the company plans to use proceeds from the offering for the development of its product candidates and research programs. Goldman Sachs led the underwriting syndicate. Shares were trading down 51 cents to $11.77.
Despite posting weaker-than-expected second-quarter results,
moved higher Friday. For the quarter ended Feb. 28, the health care facilities owner reported earnings from continuing operations of $1.6 million, or 11 cents a share, on revenue of $64.1 million. Analysts expected earnings of 21 cents a share on revenue of $65.2 million. During the year-earlier period, the company posted earnings of $2.9 million, or 25 cents a share, on revenue of $49.7 million.
Looking ahead, Horizon Health now sees 2006 earnings of 92 cents to 97 cents a share, down from an earlier view of $1.13 to $1.17 a share. For 2007, the company expects earnings of $1.26 to $1.30 a share. The guidance for both periods includes nine facilities that were acquired during the second quarter and the acquisition of a Delaware facility that closed on April 1. Analysts project 2006 earnings of $1.06 a share and 2007 earnings of $1.39 a share. Shares were trading up $1.30, or 7%, to $20.80.
slid 11% after the genetic testing company received a delisting notice from Nasdaq and said it plans to restate its results for the second and third quarters of 2005. The restatement relates to a second-quarter settlement of escrow claims that pertain to its December 2001 acquisition of Lifecodes. Stock that was received from the settlement, valued at $1.6 million, should have been recorded as a non-operating gain and an acquisition of treasury stock, the company said. The restatement won't have a negative effect on the company's results for 2005, it said.
Orchid isn't in compliance with Nasdaq's continued listing requirements because it has not yet filed its annual report for 2005. The company, which is currently working with its auditor to complete the report, has requested a hearing before Nasdaq officials to appeal the delisting notice. Shares were trading down 59 cents to $4.76.
fell 8% after the specialty pharmaceutical company said it would sell about 5.77 million units priced at almost $6.97 a share, resulting in net proceeds of $37.7 million. Each unit consists of one share and one warrant to buy 0.3 shares of stock, with an exercise price of $7.97 a share. The warrants will be exercisable from October 12 of this year through April 12, 2011. The company expects to close the stock and warrant deal April 12. Shares were trading down 53 cents to $6.45.
Other health care volume movers included
, down 35 cents to $24.74;
, down 33 cents to $21.60;
, down 34 cents to $8.70;
, down 16 cents to $34.68;
, down 8 cents to $2.69;
St. Jude Medical
, up 6 cents to $37.12;
, down 64 cents to $53.87;
, down 2 cents to $5.99;
, down 54 cents to $50.95;
, down $1.09 to $70.76;
Johnson & Johnson
, down 59 cents to $57.91;
, down 21 cents to $24.60;
, up 10 cents to $14.25; and
, down 11 cents to $18.90.